Brief: Verastem Oncology Announces New Ramp 201 Molecular Profiling And External Control Arm Analyses Describing Outcomes For Avutometinib Plus Defactinib In Recurrent Low-Grade Serous Ovarian Cancer To Be Presented At Igcs 2026
02/10/2026 12:32
BRIEF-Verastem Oncology Announces New Ramp 201 Molecular Profiling And External Control Arm Analyses Describing Outcomes For Avutometinib Plus Defactinib In Recurrent Low-Grade Serous Ovarian Cancer To Be Presented At Igcs 2026 Oct 2 (Reuters) - Verastem Inc VSTM.O:
VERASTEM ONCOLOGY ANNOUNCES NEW RAMP 201 MOLECULAR PROFILING AND EXTERNAL CONTROL ARM ANALYSES DESCRIBING OUTCOMES FOR AVUTOMETINIB PLUS DEFACTINIB IN RECURRENT LOW-GRADE SEROUS OVARIAN CANCER TO BE PRESENTED AT IGCS 2026
VERASTEM - AVUTOMETINIB PLUS DEFACTINIB ACHIEVES 18% ORR, 13 MONTHS MEDIAN PFS IN TRIPLE WILD-TYPE LGSOC
VERASTEM - AVUTOMETINIB PLUS DEFACTINIB ACHIEVES 44% ORR, 94% DISEASE CONTROL RATE IN JAPANESE LGSOC STUDY
VERASTEM - AVUTOMETINIB PLUS DEFACTINIB SHOWS HIGHER ORR AND PFS VERSUS CONVENTIONAL CARE IN LGSOC
Source text: ID:nBw8zfP1Ta
Further company coverage: VSTM.O
((Reuters.Briefs@thomsonreuters.com;;))